Clinical trials / NCT05178862
NCT05178862Phase 3Terminated

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Study sponsor: Scynexis, Inc. · SCYX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2025-11-07Actual
Enrollment · participants68Actual
Source updated2026-08-10Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: All-cause mortality (US FDA Only) Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only)

+ After

Measure: All-cause Mortality Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only)

Check registry source

· 3 fields changed

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

31 Dec 2026

+ After

7 Nov 2025

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source

· 3 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

220 participants (planned)

+ After

68 participants (actual)

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source